论文部分内容阅读
目的:观察血管抑素基因联合5-氟尿嘧啶(5-FU)腹腔化疗对预防大肠癌术后腹腔种植的作用。方法:RT-PCR扩增血管抑素基因,构建重组腺病毒载体。建立人结肠癌LoVo细胞腹腔种植的模型,给予血管抑素基因联合5-FU腹腔化疗,并观察其对大肠癌细胞腹腔种植的影响。结果:各组裸鼠的致瘤率和死亡率为100%。血管抑素基因联合5-FU腹腔化疗治疗组的腹水出现时间晚〔(22.3±5.4)d〕,荷瘤生存时间长〔(47.3±8.4)d〕,治疗组肿瘤组织中血管抑素基因表达为阳性,肿瘤微血管密度(3.64±0.58)明显低于其他各组。结论:血管抑素的基因治疗与传统的腹腔化疗联合应用,可能是预防大肠癌术后腹腔种植的一种有效方法。
Objective: To observe the effect of angiostatin gene combined with 5-fluorouracil (5-FU) intraperitoneal chemotherapy on the prevention of postoperative abdominal colon cancer implantation. Methods: The angiostatin gene was amplified by RT-PCR and the recombinant adenovirus vector was constructed. The model of peritoneal implantation of human colon cancer LoVo cells was established. The combination of angiostatin gene and 5-FU intraperitoneal chemotherapy was applied to observe the effect of angiostatin gene on the peritoneal implantation of colorectal cancer cells. Results: The tumorigenicity and mortality of nude mice in each group were 100%. The ascites of the angiostatin gene combined with 5-FU intraperitoneal chemotherapy was delayed (22.3 ± 5.4) days, and the tumor-bearing survival was prolonged (47.3 ± 8.4) days. The expression of angiostatin gene Was positive, tumor microvessel density (3.64 ± 0.58) was significantly lower than the other groups. Conclusion: The combination of angiostatin gene therapy and traditional intraperitoneal chemotherapy may be an effective method to prevent peritoneal implantation after colorectal cancer surgery.